Novel Therapy for Life Threatening Invasive Fungal Infections

A key component of NanoElectroPlex TM nanoparticles exhibits potent broad-spectrum anti-fungal activity in vitro and in vivo. This component shows minimal toxicity and immunogenicity, and is active against fungal isolates that are resistant or refractory to fluconazole, the most widely used antifungal drug. AparnaBio has secured an exclusive license to intellectual property covering this therapeutic application, has received grant funding to extend our early findings, and seeks partnership opportunities to advance this novel drug candidate through pre-clinical testing and to clinical approval.

To learn more and discuss partnership possibilities contact Business Development at busdev@aparnabio.com.